Antimicrobial susceptibility testing

Antimicrobial susceptibility testing (AST) is a standardized set of in-vitro laboratory methods used to determine the degree of sensitivity or resistance of a specific microorganism to a range of antimicrobial drugs. Its core output is the Minimum Inhibitory Concentration (MIC). The international standard ISO 20776-1:2019 specifies the reference broth microdilution method. Within enterprise risk management, AST serves as a Key Risk Indicator (KRI) for pharmaceutical R&D and healthcare operations. It provides essential data for assessing risks of clinical trial failure, ineffective patient treatment, and non-compliance, directly measuring the phenotypic response of microbes to drugs.

In ERM, AST is applied across the value chain. 1) **Risk Identification:** Pharmaceutical firms use AST surveillance data (e.g., from EUCAST, CLSI) to identify resistance trends, informing the Target Product Profile for new drugs and mitigating market access risk. 2) **Operational Risk Control:** Healthcare providers integrate AST into antimicrobial stewardship programs to guide prescriptions, reducing risks of treatment failure and associated liabilities. This can improve appropriate antibiotic use by over 20%. 3) **Compliance Management:** Laboratories must adhere to standards like ISO 15189 and ISO 20776-1, ensuring data integrity and mitigating risks of accreditation loss or legal action, thereby maintaining a 100% audit pass rate.

Taiwanese enterprises face three key challenges: 1) **Divergent Standards:** Discrepancies between locally adopted CLSI guidelines and the EUCAST standards used by global partners can create data harmonization issues. Mitigation involves establishing a regulatory intelligence function to perform gap analysis. 2) **Limited Automation and Data Integration:** Manual processes and siloed data hinder effective resistance surveillance. The solution is a phased adoption of automated systems and a Laboratory Information Management System (LIMS). 3) **Talent Shortage:** A lack of experts who can translate AST data into risk insights. Mitigation strategies include industry-academia partnerships and implementing software with expert systems.

Winners Consulting specializes in risk management for Taiwan's biotech and healthcare sectors, focusing on Antimicrobial susceptibility testing. Our expert team has helped over 100 Taiwanese companies establish management systems compliant with ISO 20776-1 and ISO 15189 within 90 days. We offer end-to-end solutions from lab process optimization to risk strategy. Free consultation: https://winners.com.tw/contact